Holen Sie sich die Stockscreener-App
33.38
0.30%
0.10
Handel nachbörslich:
33.38
Schlusskurs vom Vortag:
$33.28
Offen:
$33.1
24-Stunden-Volumen:
588.65K
Relative Volume:
0.76
Marktkapitalisierung:
$1.45B
Einnahmen:
$384.10M
Nettoeinkommen (Verlust:
$-9.07M
KGV:
-238.43
EPS:
-0.14
Netto-Cashflow:
$11.10M
1W Leistung:
+3.83%
1M Leistung:
+18.83%
6M Leistung:
+69.10%
1J Leistung:
+27.55%
1-Tages-Spanne:
$32.95
$33.81
1-Wochen-Bereich:
$32.00
$33.81
52-Wochen-Spanne:
$17.82
$33.98
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
23 OLD BOND STREET, FLOOR 3, LONDON
Vergleichen Sie KNSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
33.38 | 2.47B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
154.11 | 67.83B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.00 | 46.74B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.52B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.86 | 20.12B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
313.13 | 14.11B | 2.99B | 1.21B | 1.13B | 25.06 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas - Barchart.com
Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Insider Sells 29,325 Shares of Stock - MarketBeat
Eben Tessari Sells 138,614 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Michael R. Megna Sells 17,000 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Sells $621,259.21 in Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighShould You Buy? - MarketBeat
BIT Capital GmbH Takes $264,000 Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
J.P. Morgan Maintains Buy Rating on Kiniksa Pharmaceuticals with $55 Price Target - AInvest
Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen - Defense World
Wedbush Issues Positive Outlook for KNSA Earnings - MarketBeat
Kiniksa Pharmaceuticals surges 11.01% on Arcalyst's market penetration - AInvest
Victory Capital Management Inc. Makes New Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect? - MSN
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High After Earnings Beat - MarketBeat
Equities Analysts Set Expectations for KNSA Q3 Earnings - Defense World
Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge - Yahoo Finance
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going - Yahoo Finance
Victory Capital Management Inc. Takes $1.18 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals Achieves 52% YoY Growth in Q2 2025, Raises Revenue Guidance - AInvest
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates - MSN
Kiniksa raises ARCALYST 2025 revenue guidance to $625M-$640M as patient penetration rises - MSN
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals International Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... By GuruFocus - Investing.com Canada
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High After Strong Earnings - Defense World
Kiniksa Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Kiniksa: Jefferies maintains Buy, raises PT to $54 from $45. - AInvest
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights and Financial Results - AInvest
Kiniksa Pharmaceuticals stock hits 52-week high at 30.8 USD By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals International Q2 2025 Earnings Call Transcript - MarketBeat
Kiniksa Pharmaceuticals Reports Q2 2025 Financial Results with 52% Growth in ARCALYST Revenue and Updates on Clinical Trials - Quiver Quantitative
Kiniksa Crushes Earnings: ARCALYST Sales Jump 52%, Company Raises 2025 Revenue Target to $640M - Stock Titan
Kiniksa Pharmaceuticals Q2 2025 Earnings Preview: $0.22 EPS, $145.21M Revenue Expected - AInvest
Cwm LLC Purchases 19,828 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of “Buy” by Analysts - Defense World
Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $39.67 - MarketBeat
Kiniksa Pharmaceuticals Announces Q2 2025 Financial Results Conference Call. - AInvest
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.80%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):